Compare Ascendis Pharma A/S (ASND) vs J M Smucker Co (SJM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs J M Smucker Co — how do they compare? Ascendis Pharma A/S trades at $254.76 (market cap $16.67B), while J M Smucker Co trades at $118.79 (market cap $12.54B). The key difference: Ascendis Pharma A/S is the larger of the two by market cap, and J M Smucker Co pays a 3.82% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | SJM | |
|---|---|---|
Market Cap | $16.67B | $12.54B |
Sector | Health | Consumer Staples |
52-Week High | $277.18 | $126.35 |
52-Week Low | $189.74 | $89.53 |
Enterprise Value | $17.04B | $19.57B |
Dividend Yield | — | 3.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.50, showing minimal daily movement with a slight decline of 0.05%. The stock maintains a bullish technical outlook with strong moving average signals, while oscillators remain neutral. Fundamentally, the company demonstrates impressive revenue growth from $51M in 2022 to $720M in 2025, though it remains unprofitable with a net loss of $228M. Analyst sentiment is overwhelmingly positive with 92% buy ratings and a $309.75 consensus price target representing 21% upside potential.
ASND presents a compelling growth story with multiple product launches driving revenue expansion, but carries significant execution risk as the company transitions to profitability. The negative shareholder equity and high debt levels require careful monitoring, though positive cash flow generation in 2025 marks an important inflection point. The stock's premium valuation reflects expectations for continued growth in its rare endocrine franchise.
SJM trades at $118.07, down 1.74% today, with a bullish technical signal supported by moving averages and oversold RSI levels. The company reported mixed fundamentals with strong revenue growth to $8.73B in 2025 but negative net income of -$1.23B. Recent dividend increases and positive earnings beats in Q4 2025 and Q1 2026 highlight management's confidence amid profitability challenges.
Wall Street maintains a cautiously optimistic outlook with 52% analyst buy ratings and a $125.11 consensus target, representing 6% upside. Key risks include persistent negative margins and high debt levels, while opportunities lie in cost controls and Uncrustables growth. The stock offers value at reasonable P/S and P/B multiples with dividend stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →
